OverviewSuggest Edit
AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs. The Company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
... Show more| Type | Public | |
| Founded | 2013 | |
| HQ | North Chicago, US | Map |
| Website | abbvie.com | |
| Employee Ratings | More |
Recent NewsAll News
- Global Human Immunodeficiency Virus (HIV) Drugs Market 2019-2025 with AbbVie, Merck, Gilead Sciences, Bristol-Myers Squibb, Janssen & GSK Dominating
- AbbVie stock up 0.2% after FDA grants upadacitinib priority review status
- Antibiotics And Antimycotics 2019 Global Market Key Players - Novartis, Bayer, Sanofi, Johnson & Johnson, Eli Lilly, Roche, GSK, Merck, AstraZeneca, AbbVie, Pfizer......
- Testosterone Replacement Therapy Market Updates Till 2026 Explore By Top Players Pfizer, Inc., Bayer AG, Eli Lilly and Company, AbbVie, Inc.
Key People/Management at AbbVie
Richard Gonzalez
Chairman of the Board and Chief Executive Officer
Carlos Alban
Executive Vice President, Commercial Operations
Timothy Richmond
Senior Vice President, Human Resources
Azita Saleki-Gerhardt
Senior Vice President, Operations
Karen Hale
Vice President, Chief Ethics and Compliance Officer
Wulff-Erik von Borcke
President, Pharmacyclics
Report incorrect company information
AbbVie Office Locations
AbbVie has offices in North Chicago, Wyandotte, Cambridge, Worcester and in 12 other locations
North Chicago, US (HQ)
1 Waukegan Rd
Cambridge, US
200 Sidney St
Barceloneta, PR
PR-2
Report incorrect company information
AbbVie Financials and Metrics
AbbVie Revenue
AbbVie's revenue was reported to be $25.64 b in FY, 2016 which is a 12.2% increase from the previous period.
| USD | |
|---|---|
Revenue (Q3, 2018) | 8.2b |
Gross profit (Q3, 2018) | 6.4b |
Gross profit margin (Q3, 2018), % | 77.7% |
Net income (Q3, 2018) | 2.7b |
EBIT (Q3, 2018) | 3.2b |
Market capitalization (15-Feb-2019) | 121.6b |
Closing stock price (15-Feb-2019) | 80.9 |
Cash (30-Sep-2018) | 8.0b |
EV | 116.6b |
AbbVie's current market capitalization is $121.6 b.
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 18.8b | 20.0b | 22.9b | 25.6b |
Revenue growth, % | 6% | 15% | 12% | |
Cost of goods sold | 4.6b | 4.4b | 4.5b | 5.8b |
Gross profit | 14.2b | 15.5b | 18.4b | 19.8b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.7b | 4.6b | 4.9b | 5.0b | 5.0b | 5.5b | 5.9b | 6.0b | 6.5b | 6.4b | 6.5b | 6.9b | 7.0b | 7.9b | 8.3b | 8.2b |
Cost of goods sold | 1.1b | 1.1b | 1.1b | 1.1b | 942.0m | 916.0m | 1.2b | 1.4b | 1.4b | 1.5b | 1.6b | 1.5b | 1.6b | 1.9b | 1.9b | 1.8b |
Gross profit | 3.6b | 3.5b | 3.8b | 3.9b | 4.1b | 4.6b | 4.8b | 4.6b | 5.0b | 4.9b | 4.9b | 5.4b | 5.4b | 6.0b | 6.3b | 6.4b |
Gross profit Margin, % | 77% | 76% | 77% | 78% | 81% | 83% | 80% | 77% | 78% | 77% | 75% | 78% | 77% | 76% | 77% | 78% |
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 9.6b | 8.3b | 8.4b | 5.1b |
Accounts Receivable | 3.9b | 3.7b | 4.7b | 4.8b |
Inventories | 1.2b | 1.1b | 1.7b | 1.4b |
Current Assets | 17.8b | 16.1b | 16.3b | 16.2b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 9.0b | 8.1b | 9.1b | 7.7b | 7.9b | 7.4b | 9.2b | 7.6b | 6.3b | 6.2b | 4.7b | 6.1b | 8.4b | 9.0b | 3.5b | 8.0b |
Accounts Receivable | 3.8b | 3.7b | 3.7b | 3.6b | 4.2b | 4.4b | 4.6b | 4.8b | 5.0b | 5.0b | 4.7b | 4.9b | 4.9b | 5.8b | 5.8b | 5.8b |
Inventories | 1.2b | 1.1b | 1.0b | 1.0b | 1.0b | 1.6b | 1.8b | 1.8b | 1.8b | 1.6b | 1.4b | 1.6b | 1.8b | 1.7b | 1.6b | 1.8b |
Current Assets | 16.5b | 17.3b | 17.8b | 17.6b | 15.4b | 16.9b | 17.9b | 16.6b | 16.8b | 16.3b | 15.5b | 17.0b | 18.9b | 20.4b | 13.8b | 18.5b |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 4.1b | 1.8b | 5.1b | 6.0b |
Inventories | (56.0m) | (203.0m) | (434.0m) | (38.0m) |
Accounts Payable | (426.0m) | (193.0m) | 1.5b | (1.2b) |
Cash From Operating Activities | 6.3b | 3.5b | 7.5b | 7.0b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 3.0b | 980.0m | 2.1b | 2.6b | 1.0b | 2.4b | 3.6b | 1.4b | 3.0b | 4.6b | 1.7b | 3.6b | 5.3b | 2.8b | 4.8b | 7.5b |
Depreciation and Amortization | 697.0m | 199.0m | 401.0m | 593.0m | 158.0m | 348.0m | 575.0m | 268.0m | 557.0m | 861.0m | 374.0m | 753.0m | 1.1b | 445.0m | 888.0m | 1.3b |
Inventories | (86.0m) | 50.0m | 97.0m | 20.0m | (75.0m) | (160.0m) | (446.0m) | 19.0m | (160.0m) | 28.0m | 71.0m | 1.0m | (119.0m) | (71.0m) | (191.0m) | (367.0m) |
Accounts Payable | 227.0m | (612.0m) | (217.0m) | (1.0m) | 188.0m | 409.0m | 1.3b | 42.0m | 89.0m | (975.0m) | (266.0m) | (530.0m) | 444.0m | 191.0m | 12.0m | 881.0m |
| USD | Y, 2018 |
|---|---|
EV/EBIT | 36.9 x |
Debt/Equity | -1 x |
Financial Leverage | -22.7 x |
AbbVie Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Stem CentRx | April 28, 2016 | $5.80 b |
Report incorrect company information
AbbVie Online and Social Media Presence
49.4k Twitter followers
AbbVie has 49.4k Twitter Followers. The number of followers has increased 1.3% month over month and increased 2.6% quarter over quarter
Report incorrect company information
AbbVie News and Updates
February 20, 2019
Global Human Immunodeficiency Virus (HIV) Drugs Market 2019-2025 with AbbVie, Merck, Gilead Sciences, Bristol-Myers Squibb, Janssen & GSK Dominating
DUBLIN, Feb. 20, 2019 /PRNewswire/ -- The "Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 - 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts" report has been added to ResearchAndMarkets.com's offering. The global human immunodeficiency virus (HIV) drugs market...
February 19, 2019
AbbVie stock up 0.2% after FDA grants upadacitinib priority review status
Shares of AbbVie, Inc. were up 0.2% in premarket trade Tuesday after the company announced that the U.S. Food and Drug Administration had assigned priority review status to its new drug application for upadacitinib, a potential therapy for adult patients with moderate-to-severe rheumatoid arthritis…
February 13, 2019
Antibiotics And Antimycotics 2019 Global Market Key Players - Novartis, Bayer, Sanofi, Johnson & Johnson, Eli Lilly, Roche, GSK, Merck, AstraZeneca, AbbVie, Pfizer......
Antibiotics And Antimycotics – Global Market Growth, Opportunities, Analysis Of Top Key Players And Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday
February 12, 2019
Testosterone Replacement Therapy Market Updates Till 2026 Explore By Top Players Pfizer, Inc., Bayer AG, Eli Lilly and Company, AbbVie, Inc.
Hypogonadism in men is primarily characterized by reduced concentration of serum testosterone, causing decreased libido, erectile dysfunction, loss of body and facial hair, decreased bone density, weakness, decreased lean body mass, increased body fat, fatigue and anemia. Posted via Industry Today. …
February 07, 2019
Bio-pharma Market to witness astonishing growth of 10.1% including key players Sanofi, Amgen, AbbVie, Merck, Biogen Idec
Advance Market Analytics, a global market research and consulting organization, have released a new study titled "Bio-pharma market - Global outlook to 2024". The study highlights influencing factors that are impacting or reinforcing market environment such as Government Policy, technological change…
February 05, 2019
Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm
SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: AbbVie Inc. (NYSE: ABBV) [click here to join this action] Macquarie Infrastructure Corporation (NYSE:MIC) [click here to join this...
Report incorrect company information
AbbVie Company Life and Culture
Report incorrect company information
AbbVie Frequently Asked Questions
When was AbbVie founded?
AbbVie was founded in 2013.
Who are AbbVie key executives?
AbbVie's key executives are Richard Gonzalez, Carlos Alban and Timothy Richmond.
How many employees does AbbVie have?
AbbVie has 30,000 employees.
What is AbbVie revenue?
Latest AbbVie annual revenue is $25.6 b.
What is AbbVie revenue per employee?
Latest AbbVie revenue per employee is $854.6 k.
Who are AbbVie competitors?
Competitors of AbbVie include Johnson & Johnson, Roche and Novartis.
Where is AbbVie headquarters?
AbbVie headquarters is located at 1 Waukegan Rd, North Chicago.
Where are AbbVie offices?
AbbVie has offices in North Chicago, Wyandotte, Cambridge, Worcester and in 12 other locations.
How many offices does AbbVie have?
AbbVie has 16 offices.